MEDICAL BIOLOGICAL DEFENSE (OP SYS DEV)

Abstract

The project supports technology refresh of fielded medical diagnostic systems and associated capabilities (e.g., assays) that contribute to the layered medical defenses against biological warfare agent threats facing U.S. Forces in the field. Efforts in this project include: (1) Joint Biological Agent Identification and Diagostic System (JBAIDS) (2) Next Generation Diagnostic System (NGDS) JBAIDS is a commercial off the shelf system that provides a critical capability to identify bacterial and viral agents in environmental surveillance and clinical specimen sample types. The JBAIDS is reaching its end of life. Replacement of JBAIDS with NGDS Increment 1 began in 2017 and will achieve full replacement by the end of FY20. The NGDS is a family of systems providing increments of diagnostic capabilities over time that address varied CBR threats across the different echelons of the Combat Health Support System. The mission of the NGDS is to provide CBR threat and infectious disease identification and Food and Drug Administration (FDA) cleared diagnostics to inform individual patient treatment and CBR situational awareness and disease surveillance. NGDS Increment 1 improves diagnostic capabilities in deployable and laboratory-based combat health support units. NGDS Inc 1 offers improved operational suitability and affordability over legacy systems by developing FDA cleared biological warfare agent (BWA) and infectious disease in vitro diagnostic (IVD) assays on an existing commercial diagnostic device with a well-established FDA regulatory history and pipeline of commercial non-BWA infectious disease diagnostic tests.

Document Details

• Document Type: Project
• Publication Date: Oct 01, 2020
• Source ID: MB7_0607384BP_7_0400_PB_2020

Tags

Readers

• Critical Infrastructure Protection in CBRN and WMD Threats.